172 related articles for article (PubMed ID: 19863693)
41. Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction.
Naldini L; Vigna E; Bardelli A; Follenzi A; Galimi F; Comoglio PM
J Biol Chem; 1995 Jan; 270(2):603-11. PubMed ID: 7822285
[TBL] [Abstract][Full Text] [Related]
42. Metalloproteinase inhibitor TIMP-1 affects hepatocyte cell cycle via HGF activation in murine liver regeneration.
Mohammed FF; Pennington CJ; Kassiri Z; Rubin JS; Soloway PD; Ruther U; Edwards DR; Khokha R
Hepatology; 2005 Apr; 41(4):857-67. PubMed ID: 15726641
[TBL] [Abstract][Full Text] [Related]
43. p75 neurotrophin receptor inhibits invasion and metastasis of gastric cancer.
Jin H; Pan Y; He L; Zhai H; Li X; Zhao L; Sun L; Liu J; Hong L; Song J; Xie H; Gao J; Han S; Li Y; Fan D
Mol Cancer Res; 2007 May; 5(5):423-33. PubMed ID: 17510309
[TBL] [Abstract][Full Text] [Related]
44. Role of plasminogen activators, metalloproteinases and the tissue inhibitor of metalloproteinase-1 in the metastatic process of human salivary-gland adenocarcinoma cells.
Azuma M; Tamatani T; Fukui K; Yoshida H; Kamogashira T; Ogino K; Suzuki T; Sato M
Int J Cancer; 1993 Jun; 54(4):669-76. PubMed ID: 8514458
[TBL] [Abstract][Full Text] [Related]
45. Endogenous urokinase lacks antifibrotic activity during progressive renal injury.
Yamaguchi I; Lopez-Guisa JM; Cai X; Collins SJ; Okamura DM; Eddy AA
Am J Physiol Renal Physiol; 2007 Jul; 293(1):F12-9. PubMed ID: 17356128
[TBL] [Abstract][Full Text] [Related]
46. Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK.
Hecht M; Heider U; Kaiser M; von Metzler I; Sterz J; Sezer O
Br J Haematol; 2007 Aug; 138(4):446-58. PubMed ID: 17593251
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of histone deacetylase activity down-regulates urokinase plasminogen activator and matrix metalloproteinase-9 expression in gastric cancer.
Lee KH; Choi EY; Kim MK; Kim KO; Jang BI; Kim SW; Kim SW; Song SK; Kim JR
Mol Cell Biochem; 2010 Oct; 343(1-2):163-71. PubMed ID: 20559690
[TBL] [Abstract][Full Text] [Related]
48. Pro-urokinase-type plasminogen activator is a substrate for hepsin.
Moran P; Li W; Fan B; Vij R; Eigenbrot C; Kirchhofer D
J Biol Chem; 2006 Oct; 281(41):30439-46. PubMed ID: 16908524
[TBL] [Abstract][Full Text] [Related]
49. TLR3 promotes hepatocyte proliferation after partial hepatectomy by stimulating uPA expression and the release of tissue-bound HGF.
Stöß C; Laschinger M; Wang B; Lu M; Altmayr F; Hartmann D; Hüser N; Holzmann B
FASEB J; 2020 Aug; 34(8):10387-10397. PubMed ID: 32539223
[TBL] [Abstract][Full Text] [Related]
50. AP-1-controlled hepatocyte growth factor activation promotes keratinocyte migration via CEACAM1 and urokinase plasminogen activator/urokinase plasminogen receptor.
Schnickmann S; Camacho-Trullio D; Bissinger M; Eils R; Angel P; Schirmacher P; Szabowski A; Breuhahn K
J Invest Dermatol; 2009 May; 129(5):1140-8. PubMed ID: 19020551
[TBL] [Abstract][Full Text] [Related]
51. Plasminogen activator inhibitor 2 (PAI2) inhibits invasive potential of hepatocellular carcinoma cells in vitro via uPA- and RB/E2F1-related mechanisms.
Jin Y; Liang ZY; Zhou WX; Zhou L
Hepatol Int; 2019 Mar; 13(2):180-189. PubMed ID: 30600477
[TBL] [Abstract][Full Text] [Related]
52. Transforming Growth Factor-Beta and Urokinase Type Plasminogen Interplay in Cancer.
Santibanez JF; Krstic J
Curr Protein Pept Sci; 2018; 19(12):1155-1163. PubMed ID: 29086689
[TBL] [Abstract][Full Text] [Related]
53. Transforming growth factor-beta1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity.
Farina AR; Coppa A; Tiberio A; Tacconelli A; Turco A; Colletta G; Gulino A; Mackay AR
Int J Cancer; 1998 Mar; 75(5):721-30. PubMed ID: 9495240
[TBL] [Abstract][Full Text] [Related]
54. Nuclear Factor I-C acts as a regulator of hepatocyte proliferation at the onset of liver regeneration.
Edelmann S; Fahrner R; Malinka T; Song BH; Stroka D; Mermod N
Liver Int; 2015 Apr; 35(4):1185-94. PubMed ID: 25293436
[TBL] [Abstract][Full Text] [Related]
55. Urokinase directly activates matrix metalloproteinases-9: a potential role in glioblastoma invasion.
Zhao Y; Lyons CE; Xiao A; Templeton DJ; Sang QA; Brew K; Hussaini IM
Biochem Biophys Res Commun; 2008 May; 369(4):1215-20. PubMed ID: 18355442
[TBL] [Abstract][Full Text] [Related]
56. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
Fisher JL; Field CL; Zhou H; Harris TL; Henderson MA; Choong PF
Breast Cancer Res Treat; 2000 May; 61(1):1-12. PubMed ID: 10930085
[TBL] [Abstract][Full Text] [Related]
57. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells.
Rosenthal EL; Johnson TM; Allen ED; Apel IJ; Punturieri A; Weiss SJ
Cancer Res; 1998 Nov; 58(22):5221-30. PubMed ID: 9823336
[TBL] [Abstract][Full Text] [Related]
58. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
[TBL] [Abstract][Full Text] [Related]
59. Expression of matrix metalloproteinases during murine chorioallantoic placenta maturation.
Teesalu T; Masson R; Basset P; Blasi F; Talarico D
Dev Dyn; 1999 Mar; 214(3):248-58. PubMed ID: 10090151
[TBL] [Abstract][Full Text] [Related]
60. Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes.
Cui H; Seubert B; Stahl E; Dietz H; Reuning U; Moreno-Leon L; Ilie M; Hofman P; Nagase H; Mari B; Krüger A
Oncogene; 2015 Jul; 34(28):3640-50. PubMed ID: 25263437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
